


### Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in this application.

#### Listing of Claims:

1. (Previously presented) A pharmaceutical composition comprising:  
(a) a compound of the formula:



or an acid addition salts thereof,

wherein

the carbon atom designated \* constitutes a center of chirality,

R<sup>4</sup> is hydrogen or -(C=O)-R<sup>12</sup>;

each of R<sup>1</sup> and R<sup>12</sup>, independently of each other, is alkyl of 1 to 6 carbon atoms,

phenyl, benzyl, pyridyl methyl, pyridyl, imidazolyl, imidazolylmethyl, or

CHR<sup>\*</sup>(CH<sub>2</sub>)<sub>n</sub>NR<sup>\*</sup>R<sup>0</sup>

wherein R<sup>\*</sup> and R<sup>0</sup>, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolylmethyl, and n = 0, 1, 2;

R<sup>5</sup> is C=O, CH<sub>2</sub>, -CH<sub>2</sub>-CO-, or SO<sub>2</sub>;

each of R<sup>6</sup> and R<sup>7</sup>, independently of the other, is nitro, cyano, trifluoromethyl,

carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy,

carboxy, hydroxy, amino, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon

atoms, cycloalkoxy of 3 to 8 carbon atoms, halo, bicycloalkyl of up to 18

carbon atoms, tricycloalkoxy of up to 18 carbon atoms, 1-indanyloxy, 2-

indanyloxy, C<sub>4</sub>-C<sub>8</sub>-cycloalkylidenemethyl, or C<sub>3</sub>-C<sub>10</sub>-alkylidenemethyl; and

each of R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, and R<sup>11</sup> independently of the others, is

(i) hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy,


carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino,

- alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halo, or
- (ii) one of  $R^8$ ,  $R^9$ ,  $R^{10}$ , and  $R^{11}$  is acylamino comprising a lower alkyl, and the remaining of  $R^8$ ,  $R^9$ ,  $R^{10}$ , and  $R^{11}$  are hydrogen, or
- (iii) hydrogen if  $R^8$  and  $R^9$  taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (iv) hydrogen if  $R^{10}$  and  $R^{11}$ , taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (v) hydrogen if  $R^9$  and  $R^{10}$  taken together are benzo; and
- (b) a pharmaceutically acceptable carrier.

2-4. (Canceled).

5. (Previously presented) A pharmaceutical composition comprising:

(a) a compound of the formula:



or an acid addition salt thereof,

in which

the carbon atom designated \* constitutes a center of chirality;

$R^4$  is hydrogen or  $-(C=O)-R^{12}$ , where

each of  $R^1$  and  $R^{12}$ , independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl, pyridyl methyl, imidazolyl, imidazolymethyl, or  $CHR^*(CH_2)_nNR^0R^0$

wherein  $R^*$  and  $R^0$ , independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolymethyl, and  $n = 0, 1, 2$ ;

R<sup>5</sup> is C=O or CH<sub>2</sub>;

each of R<sup>6</sup> and R<sup>7</sup>, independently of the other is alkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms; C<sub>4</sub>-C<sub>6</sub>-cycloalkylidenemethyl, C<sub>2</sub>-C<sub>10</sub>-alkylidenemethyl, C<sub>6</sub>-C<sub>18</sub>-bicycloalkoxy, C<sub>6</sub>-C<sub>18</sub>-tricycloalkoxy, 1-indanyloxy, or 2-indanyloxy;

each of R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, and R<sup>11</sup>, independently of the others, is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, halo, carbamoyl, acetoxo, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, and alkoxy of 1 to 10 carbon atoms; and

(b) a pharmaceutically acceptable carrier.

6-18. (Canceled).

19. (Previously presented) The pharmaceutical composition of claim 1, wherein said compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.

20-29. (Canceled).

30. (Previously presented) The pharmaceutical composition of claim 5, wherein said compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.

31-40. (Canceled).

41. (Currently amended) The pharmaceutical composition of claim 1 or 5, wherein the compound is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) propanoate; (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) acetate; (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) pentanoate; (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) benzoate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1-oxoisoindolin-2-yl)propanoylamino) acetate; (3-[4-(acetylamino)-1,3-dioxoisoindolin-2-yl]-

3-(3-ethoxy-4-methoxyphenyl) propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; (3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; N-acetyl-(3-(3-ethoxy-4-methoxyphenyl)-3-(5-methyl-1,3-dioxoisindolin-2-yl)propanoylamino)acetate; N-acetyl-(3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(4-methyl-1,3-dioxoisindolin-2-yl)propanoylamino) acetate; (3-[5-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propanoylamino) acetate; (3-(1,3-dioxobenzo[e]isoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)acetate; (3-(3-ethoxy-4-methoxyphenyl)-3-phthalimido-propanoylamino)pyridine-3-carboxylate; (3-[4-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoylamino)acetate; (N-acetyl-3-[4-(acetylamino)-1,3-dioxoisindolin-2-yl]-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoylamino)acetate; or (3-(3-ethoxy-4-methoxyphenyl)-3-(1-oxoisindolin-2-yl)propanoylamino)acetate.

42. (Previously presented) The pharmaceutical composition of claim 41, wherein the compound is a substantially chirally pure (R)-isomer or a substantially chirally pure (S)-isomer.